Normunity is focused on developing innovative anti-cancer therapies that target the complex interactions between the immune system and tumors. The company emphasizes the importance of identifying novel cancer drug targets that are tumor-specific, broadly expressed across various cancer types, and capable of evading immune surveillance. By leveraging insights from their collaboration with the Lieping Chen lab at Yale, Normunity has developed a proprietary discovery process that uncovers proteins that tumors exploit to create immunosuppression. This approach aims to reveal critical attributes of these proteins, which can then be targeted to enhance the effectiveness of anti-cancer treatments.

The company’s drug development pipeline includes a range of biologic medicines, such as therapeutic antibodies and bispecific antibodies, designed to address the unmet needs in treating solid tumors. Normunity employs advanced platforms for drug discovery that utilize high-throughput, physiologically relevant screening methods to systematically explore the interactions between cancer and the immune system. This integrated approach not only facilitates the identification and validation of novel targets but also supports the development of new therapies that can potentially transform cancer treatment by effectively engaging the immune response against tumors.

United States

Normunity is a biotechnology company creating novel anti-cancer therapies that address untapped biology at the interface of the immune system and the tumor to target mechanisms that impact tumor growth and circumvent immune surveillance and tumor clearance. The company is using these novel targets to build a pipeline of anti-cancer medicines, including therapeutic antibodies, bispecific antibodies, and payload-carrying biologics. The company’s lead program, NRM‑823, is a T cell engager with tumor-specific targeting for multiple solid tumors and is expected to enter the clinic in 2025. Normunity is located in Boston, MA, and New Haven, CT.

Normunity

Company Details